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As the ﬁrst discovered gaseous signaling molecule, nitric oxide (NO) affects a number of cellular pro-
cesses, including those involving vascular cells. This brief review summarizes the contribution of NO to
the regulation of vascular tone and its sources in the blood vessel wall. NO regulates the degree of
contraction of vascular smooth muscle cells mainly by stimulating soluble guanylyl cyclase (sGC) to
produce cyclic guanosine monophosphate (cGMP), although cGMP-independent signaling [S-
nitrosylation of target proteins, activation of sarco/endoplasmic reticulum calcium ATPase (SERCA) or
production of cyclic inosine monophosphate (cIMP)] also can be involved. In the blood vessel wall, NO is
produced mainly from L-arginine by the enzyme endothelial nitric oxide synthase (eNOS) but it can also
be released non-enzymatically from S-nitrosothiols or from nitrate/nitrite. Dysfunction in the production
and/or the bioavailability of NO characterizes endothelial dysfunction, which is associated with cardio-
vascular diseases such as hypertension and atherosclerosis.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Nitric oxide (NO) is a free radical (1), generated naturally by
electrical discharges [e.g. lightning) (2)], produced industrially as
an important chemical intermediate (3), or released as an air
pollutant from automobile engines or fossil fuel power plants (4, 5).
Its potential endogenous production as an endothelium-derived
relaxing factor (6) was ﬁrst proposed independently by Robert
Furchgott and Louis Ignarro in 1986 (7, 8) and conﬁrmed in sub-
sequent studies (9e12). It thus was the ﬁrst gaseous molecule
accepted to be a signaling mediator in the organism (13). It soon
appeared that NO plays a key role in the physiological regulation of
the cardiovascular system, since abnormalities in its productions
and/or bioavailability accompany or even precede diseases such as
hypertension, atherosclerosis and angiogenesis-associated disor-
ders (14e17). NO also exerts physiological functions in the nervous
and immune systems, contributing to the regulation of behavior,
gastrointestinal motility, and defense mechanisms against infec-
tious disease and tumors (18e24). This brief review focuses on thearmaceutical Biotechnology,
iversity of Hong Kong, 2/F,
Shing Faculty of Medicine, 21
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d/4.0/).sources of NO in the blood vessel wall and its role in the regulation
of vascular tone.
2. Components of the vascular wall
Blood vessels are composed of three layers: an intimal mono-
layer of endothelial cells, medial vascular smooth muscle and the
adventitia or tunica externa (Fig. 1) (25, 26).
The intimal monolayer of endothelial cells covers the entire
vascular tree, from the heart to the smallest capillaries, thus
forming the interior surface of all blood vessels, which functions a
barrier between the blood in the lumen and the surrounding tis-
sues (25). The endothelium plays a modulator role in the basal and
dynamic regulation of blood vessel diameter by releasing
endothelium-derived NO (Fig. 2) (6,27e30) and contracting pros-
tanoids and peptides (31e38), and by initiating endothelium-
dependent hyperpolarizations (39e44).
The vascular smooth muscle layer mediates the constriction
and dilatation of the blood vessels (25). Contractions of vascular
smooth muscle cells can be initiated by mechanical (intraluminal
pressure, stretch) or pharmacological activation (i.e., by binding of
ligands to cell surface receptors), which increase the intracellular
calcium concentration either by release from internal stores
(sarcoplasmic reticulum) or by inﬂux into the cell following
opening of calcium channels in the plasma membrane (Fig. 3)
(45e52). The intracellular free calcium ions bind to calmodulin andnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Structure of arterial wall. The arterial wall is composed of three layers: tunica
intima (endothelial cells and internal elastic membrane), tunica media (vascular
smooth muscle cells and external elastic membrane), and tunica externa (adventitia;
contains perivascular adipose tissue cells, ﬁbroblast cells, collagen ﬁbers and nerve
endings).
Fig. 3. Increased intracellular calcium stimulates contraction of vascular smooth
muscle cells 1. Mechanical or pharmacological activation increases the intracellular
calcium (Ca2þ) concentration either from internal stores (sarcoplasmic reticulum, SR)
or by inﬂux into the cell following opening of calcium channels in the plasma mem-
brane; 2. The intracellular free calcium ions bind to calmodulin and the calcium-
calmodulin complex activates myosin light chain kinase (MLCK); 3. Activated MLCK
phosphorylates the myosin light chain (MLC), which leads to cross-bridge formation
between the myosin heads and the actin ﬁlaments; 4. Cross-bridge formation results in
contraction of the smooth muscle cell. Calcium channels: Receptor-operated channel
(ROC); store-operated channel (SOC); voltage-dependent calcium channel (VDCC).
IP3R: inositol 1,4,5-trisphosphate (IP3) receptor-mediated calcium release. RyR: rya-
nodine receptor-mediated calcium release. MLCP: myosin light chain phosphatase.
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nase (MLCK). MLCK phosphorylates the myosin light chain (MLC),
which leads to cross-bridge formation between the myosin heads
and the actin ﬁlaments, resulting in contraction of the smooth
muscle cells (Fig. 3) (53e59).
The adventitia (Fig. 1) contains nerve endings, perivascular
adipose tissue (PVAT) and connective elements (ﬁbroblasts and
collagen ﬁbers) that insure adherence to the surrounding organs.
Components of the adventitia are also involved in vascular devel-
opment and remodeling (60e64), immune surveillance and in-
ﬂammatory cell trafﬁcking (65e70), and signal exchanges between
the blood vessel and the tissue inwhich it resides (60, 69,71e74). In
particular, the adipocytes of PVAT, like all fat cells, secrete adipo-
kines which contribute to the regulation of vascular tone. ForFig. 2. Endothelial nitric oxide synthase (eNOS) can be activated in calcium-
dependent or- independent ways. On the one hand, agonists, such as acetylcholine,
bradykinin and histamine, act on speciﬁc receptors (R) on the endothelial cell mem-
brane to increase the intracellular concentration of calcium, which binds to calmodulin
(CaM) and leads to the activation of calmodulin-binding domain of eNOS to produce
nitric oxide (NO). On the other hand, phosphorylation of eNOS independently of the
calcium concentration is also important for the activation of the enzyme. Thr495 is an
inhibitory site but Ser635 and Ser1179 are activation sites. The responses to hemo-
dynamic shear stress and hormones are mediated mainly through this calcium-
independent pathway.example, in isolated rat aortic rings, the presence of PVAT decreases
contractions to norepinephrine, an effect attributable to transfer-
able vasodilator substances (75), termed “adipose-derived relaxing
factors” (ADRF), which can cause direct relaxation of the vascular
smooth muscle that they surround or, if and when they (e.g. adi-
ponectin and angiotensin 1e7) reach endothelial cells, stimulate
the production of NO (76e84). However, adipocytes also can pro-
duce adipokines (e.g. lipocalin-2) which can curtail this production
(85, 86).
3. Sources of vascular nitric oxide
Although in the blood vessel wall NO is mainly produced from L-
arginine by endothelial NOS (eNOS), other mechanisms of vascular
NO production exist (87e90).
3.1. L-arginine and nitric oxide synthases
L-arginine is the ﬁrst discovered and best-characterized source
of NO as substrate for NOS (10,91e93). Three distinct genes encode
NOS isozymes which catalyze the production of NO from L-argi-
nine: neuronal NOS (nNOS or NOS-1), cytokine-inducible NOS
(iNOS or NOS-2) and endothelial NOS (eNOS or NOS-3) (89,94,95).
Triple NOSs null mice exhibit reduced endothelium-dependent
relaxations (due mainly to blunted endothelium-dependent hy-
perpolarizations) and have a shorter life expectancy with acceler-
ated appearance of cardiovascular diseases including hypertension,
cardiac hypertrophy, diastolic heart failure, arteriosclerosis and
myocardial infarction (96).
The production of NO from L-arginine by NOS requires the
presence of various co-factors including tetrahydrobiopterin (BH4),
ﬂavin adenine dinucleotide, ﬂavin mononucleotide, calmodulin
and iron protoporphyrin IX (haeme) (94,97). The three NOS iso-
forms are synthesized as monomers, and need to form dimers
(Fig. 4) in order to bind BH4 and the substrate L-arginine to catalyze
NO$ production (98). The monomers generate O2$ instead of NO$
from their oxygenase domain; a condition which is referred to as
Fig. 4. Homodimers of nitric oxide synthase (NOS). I, as monomers, NOS produce O2 instead of NO; II, even as homodimers, signiﬁcant O2 production will occur when the
effective concentrations of L-arginine (L-Arg) falls below levels required to saturate the enzyme; III, when sufﬁcient L-arginine and tetrahydrobiopterin (BH4) bind to coupled NOS,
the electron ﬂux provided by nicotinamide adenine dinucleotide phosphate (NADPH) passes through ﬂavin adenine dinucleotide (FAD), ﬂavin mononucleotide (FMN), calmodulin
(CaM) and iron protoporphyrin IX (Haeme Fe), and is eventually used in NO production. BH4 is essential for NOS coupling and reactive oxygen species (ROS) oxidize BH4 to the BH3$
radical, leading to NOS uncoupling. The endogenous competitive inhibitor asymmetrical dimethyl arginine (ADMA) and arginase both reduce the L-arginine binding to NOS which
decreases NO production.
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the NOS enzyme, its coupling is more important for the production
of NO (99,100).
Neuronal NOS produces NO both in the central and peripheral
nervous systems and thus plays a role in cell communication (19,
23, 24,101). NO produced by nNOS is implicated in the regulation
of neuronal excitability and ﬁring, in long-term potentiation or
depression of synaptic plasticity, as well as in memory and learning
processes. Moreover, NO produced by nNOS regulates the release of
neurotransmitters such as acetylcholine, histamine and serotonin
(102,103). Neuronal NOS is also expressed in cardiac and skeletal
myocytes (104,105), smooth muscle and endothelial cells (106,107),
the adventitial layer of penile arteries (108), and cells of macula
densa in the kidney (109). A selective inhibitor of nNOS, S-methyl-L-
thiocitrulline (SMTC), reduces the basal blood ﬂow in the normal
human forearm and coronary circulating, without affecting eNOS-
mediated vasodilatation induced by acetylcholine or shear stress
(110,111). In vitro experimental data implicates nNOS-derived NO in
the local regulation of vascular tone independently of the central
nervous system (112). Selective inhibition of nNOS by SMTC in
explanted whole rat kidneys decreases afferent and efferent arte-
riolar diameters but does not affect vasodilatation in response to
the endothelium-dependent vasodilator acetylcholine (113). Vinyl-
L-N-5-(1-imino-3-butenyl)-L-ornithine (L-VNIO; another selective
inhibitor of nNOS) increases the arterial vasoconstriction and local
norepinephrine concentration in response to perivascular sympa-
thetic nerve stimulation in mesenteric arteries (114). However,
nNOS inhibition does not reduce the vasoconstriction to exogenous
norepinephrine, indicating that nNOS-derived NO may affect
neurotransmitter release from perivascular sympathetic nerves
(114). Neuronal NOS also participates in neurogenic vasodilation in
the rat skin microvasculature (115). NO produced by nNOS not only
initiates but also participate in maintenance of penile erectile
(108,116e119) and decreased expression of nNOS is found in pa-
tients with erectile dysfunction (120). In arteries of spontaneously
hypertensive rats (SHR) but not in normotensive Wistar-Kyoto
(WKY) rats, nNOS is expressed in the smooth muscle cells and its
activation is stimulated by angiotensin II (106). Acute hypoxiaincreases nNOS expression but reduces its activity due to substrate
deprivation, whereas chronic hypoxia induces increased synthesis
and activity of nNOS which attenuate hypoxia-induced vasocon-
striction (121,122). Vascular injury induces expression of nNOS in
the intima and the medial smooth muscle cells and selective inhi-
bition of this isoform augments the responses to various vasocon-
strictors, suppresses the production of cyclic guanosine
monophosphate (cGMP), and exacerbates neointimal formation
(123). Furthermore, the expression of vascular nNOS is also up-
regulated by stimulation with angiotensin II, platelet-derived
growth factor or statins (123e125).
The expression/presence of inducible NOS is minimal under
physiological conditions. However, this isoform is calcium-
insensitive and continuously produces NO once it is expressed
(126). Induction of iNOS occurs mainly during infection, chronic
inﬂammation and in tumors (127). The activation of iNOS promoter
requires interferon regulatory factor 1 and nuclear factor К-light-
chain-enhancer of activated B cells, explaining why expression of
iNOS is characteristic of inﬂammation (128e136). Inﬂammation-
induced iNOS expression in the endothelium but not in adventitia
may contribute to vascular dysfunction by limiting the availability
of BH4 for eNOS (137). The production of iNOS within vascular
smooth muscle cells following exposure to pro-inﬂammatory cy-
tokines is a major cause of the hypotension, cardiodepression and
vascular hyporeactivity in septic shock (138e142).
However, eNOS is the major isoform regulating vascular func-
tion (97,143). The activity of eNOS (Fig. 4), and thus the production
of NO can be initiated/enhanced by several stimuli (Fig. 2) including
shear stress (30,144e149), acetylcholine (150e153), bradykinin
(154e157), histamine (158e162) and 17b-estradiol (163e167), in
both calcium-dependent and -independent manners. Agonists,
such as acetylcholine, bradykinin and histamine, act on speciﬁc
receptors on the endothelial cell membrane to increase the intra-
cellular concentration of calcium, which binds to calmodulin and
leads to the activation of calmodulin-binding domain of eNOS
(Fig. 4) (168e171). This facilitates electron ﬂux from the reductase
to the oxygenase domains of the enzyme for NO production (172).
On the other hand, phosphorylation of eNOS independently of the
Fig. 5. Nitric oxide (NO¡) produce by cytochrome P450 reductase (CPR) from ni-
trate. The endothelium-derived NO produced by CPR from nitrate is a supplement for
NO produced by eNOS in arteries of the spontaneously hypertensive rat, and reduces
the contractions to agonists. However, reactive oxygen species (ROS) signiﬁcantly
eliminate the NO production thus restoring the contractions.
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enzyme because it facilitates the active ﬂux of electrons from the
reductase to the oxygenase domains (172). Phosphorylation is a
post-translational modiﬁcation, which adds a phosphate (PO43)
group to eNOS by kinases; the phosphate, in turn, is removed by
phosphatases (173e177). This modiﬁcation alters the activity of
eNOS and different sites of phosphorylation can have opposing
effects (178). Thus, for eNOS, Ser1177 (or Ser1179 depending on the
species) is an activation site and Thr495 is an inhibitory site. Protein
kinase A (PKA) and protein kinase B (Akt) activate eNOS by phos-
phorylating Ser1177 in response to various stimuli (149,174). By
contrast, hydrogen peroxide and bradykinin activate eNOS to pro-
duce NO by elevating both Ser1177 phosphorylation and Thr495
dephosphorylation (179,180). Increases in NO release induced by
increases in hemodynamic shear stress and 17b-estradiol are
mediated mainly through this calcium-independent pathway
(149,163,168). In particular, shear stress induces phosphorylation of
eNOS at Ser1179 and Ser635 in a PKA-dependent manner (144,181).
In addition, herbal (e.g. aurantio-obtusin and puerarin) can regulate
vascular tone by eNOS phosphorylation in an Akt-dependent
manner (182,183).
3.2. S-nitrosothiols
S-nitrosothiols such as S-nitrosohemoglobin and S-nitro-
soglutathione serve not only as downstream NO products regu-
lating protein expression and function but also as sources of NO
(87). In endothelial cells, S-nitrosothiols can be formed from
exogenous S-nitrosothiol donors (i.e., S-nitrosoglutathione) or from
endogenous NO produced by eNOS (184). In addition, NO groups
can be transferred from a donor S-nitrosylated protein to an
acceptor S-nitrosylation substrate in multi-protein complex situa-
tions (185). These S-nitrosoproteins, with a half-life of around one
hour, exist mainly in the mitochondria and peri-mitochondrial
compartment of endothelial cells (184). There is also a circulating
pool of S-nitrosoalbumin in the plasma whose levels are positively
related to NOS activity. Thus, NOS inhibition results in a decrease of
S-nitrosoalbumin but an increase of low-molecular-weight S-
nitrosothiols such as S-nitrosoglutathione. S-nitrosoglutathione
can transfer its NO group to the reactive thiols (cysb93) of hemo-
globin, and the resulting S-nitrosohemoglobin can transfer the NO
group to membrane-associated band 3 protein of erythrocytes; a
process controlled by the oxygen level in the blood (186). S-nitro-
sothiols are stable compounds at 37 C and pH 7.4 in the presence of
transition metal ion chelators (187). The liberation of NO is pro-
moted by trace amounts of transition metal ions (Cu2þ or Fe2þ)
(188), ﬂash photolysis or by the combination of the two (189).
Dithiothreitol (thiol-preserving agent) and vitamin C (antioxidant)
stimulate NO release from S-nitrosothiols to induce capillary
morphogenesis (190). By releasing NO, S-nitrosothiols are more
powerful vasodilators than nitroglycerin and potent inhibitors of
platelet aggregation; the latter can be achieved at lower concen-
trations than those required to elicit vasodilatations (191,192).
3.3. Nitrite and nitrate
Nitrite and nitrate are not only the products of the metabolism
of NO but also act as a reservoir (87). Indeed, under certain con-
ditions, different enzymes [hemoglobin, myoglobin, xanthine
oxidoreductase, mitochondrial cytochrome oxidase, aldehyde de-
hydrogenase 2, cytochrome P450 reductase and cytochrome P450]
can catalyze the reduction of nitrite or nitrate to generate NO.
Hemoglobin is an iron-containing protein in the red blood cells,
which carries and transports oxygen in the circulation system
(193e196). It is an oxygen sensor and produces NO from nitriteunder hypoxic conditions. Hypoxia causes a quaternary structural
change in hemoglobin from oxyhemoglobin to deoxyhemoglobin.
When hemoglobin is 40e60% saturated with oxygen and at pH 6.4,
it generates NO from nitrite at a maximal rate (197). Myoglobin is
also an iron- and oxygen-binding protein which is present in
muscle cells. Deoxymyoglobin reduces nitrite to NO at a rate 36
times faster than deoxyhemoglobin in vitro (198). As oxygen sen-
sors, hemoglobin and myoglobin shift from being NO scavengers to
NO producers in hypoxia; this perception of decreased oxygen
concentrations then, by releasing NO, induces vasodilatation and
increases the blood supply to the hypoxic tissues (199e201). The
enzyme xanthine oxidoreductase also produces NO from nitrate
and nitrite in anoxic tissues; this mechanism protects against
ischemia-reperfusion injury (202,203). Likewise, mitochondrial
cytochrome c oxidase produces NO fromnitrite in themitochondria
under hypoxic conditions; this NO production increases with
decreasing pH (204). The production of NO by the latter two en-
zymes may be important for the redistribution of blood ﬂow to
ischemic tissue (204,205). By contrast, aldehyde dehydrogenase 2
(ALDH2) effectively converts organic nitrate compounds, such as
nitroglycerin, to NO under normoxic conditions (206,207). Both
cytosolic and mitochondrial ALDH2 can catalyze the bioactivation
of exogenous nitroglycerin; however, an endogenous substrate for
this enzyme has not been identiﬁed (206,207). The activity and
expression of ALDH2 in the vascular system are reduced in the case
of tolerance to organic nitrates (208,209).
Cytochrome P450 reductase and cytochrome P450 induce NO
release by reducing nitrate and nitrite, respectively (210). Nitrate
(transformed to NO by cytochrome P450 reductase) has been
identiﬁed as another endothelial source of NOS-independent NO,
which is only present in SHR arteries but not in those of normo-
tensive WKY rats (Fig. 5) (90). Indeed, in the presence of NOS and
cyclooxygenase inhibitors, in aortic rings with endothelium of SHR,
but not of WKY, contractions to phenylephrine and prostaglandin
E2 were smaller than in preparations without endothelium; this
endothelium-dependent depression of contractions was abolished
when the downstream NO signaling pathway was inhibited [by NO
scavengers and inhibitors of soluble guanylyl cyclase (sGC)]. Such
endothelium-dependent, eNOS-independent depression of con-
tractions was larger in preparations of 36 than 18 weeks old SHR,
thus suggesting that the chronic elevation in arterial blood pressure
plays a role in the development of NOS-independent NO release
(90). However, in the absence of cyclooxygenase inhibition, the
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masked by reactive oxygen species (90), which supports the
concept that oxidative stress play an important role in the endo-
thelial dysfunction accompanying hypertension (211e215). The
endothelium-dependent, cytochrome P450 reductase-mediated
NO release from nitrate may serve as a compensatory mechanism
to restore NO availability during endothelial dysfunction. Indeed,
deﬁcient production of NO by its canonical source (eNOS) is a
feature of endothelial dysfunction associated with hypertension
(216e219).4. Nitric oxide and vascular tone
Endothelium-derived NO is a powerful vasodilator (6e11). It
stimulates soluble sGC in the vascular smooth muscle cells to
induce formation of cGMP (12,220e223). Cyclic GMP activates
protein kinase G, which promotes the reuptake of cytosolic calcium
into the sarcoplasmic reticulum, the expulsion of calcium out of the
cell, and the opening of calcium-activated potassium channels
(Fig. 6) (224e228). The intracellular concentration of calcium de-
creases and MLCK can no longer phosphorylate myosin and relax-
ation of the smooth muscle cells ensues (Fig. 6) (49,229e232). In
addition, NO can affect cellular activity independently of sGC-
activation (233). Thus, NO stimulates the sarco/endoplasmic retic-
ulum calcium ATPase (SERCA) reducing the intracellular calcium
concentration and causing relaxation of the smooth muscle; NO-
derived peroxynitrite (ONOO) can directly enhance SERCA activ-
ity by S-glutathiolation (Fig. 6) (234). In the presence of an electron
acceptor, NO reacts with the cysteine thiols to form S-nitrosylated
proteins (235). Such S-nitrosylation reactions are speciﬁc in that
not every cysteine-containing protein is S-nitrosylated and notFig. 6. Regulation of vascular tone by nitric oxide (NO). NO regulates vascular tone
by three different signaling pathways. I: NO stimulates soluble guanylyl cyclase (sGC)
in the vascular smooth muscle cells to induce formation of cyclic guanosine mono-
phosphate (cGMP). Cyclic GMP activates protein kinase G (PKG), which prevents the
calcium inﬂux from voltage-dependent calcium channel (VDCC) and calcium release
mediated by inositol 1,4,5-trisphosphate (IP3) receptor (IP3R). PKG also acts on sarco/
endoplasmic reticulum calcium ATPase (SERCA) to promote the reuptake of cytosolic
calcium into the sarcoplasmic reticulum (SR). The intracellular calcium concentration
decreases and calmodulin is inactivated which no longer able to activate myosin light
chain kinase (MLCK). Calcium depletion also increases the activity of myosin light
chain phosphatase (MLCP). The actin-myosin cross-bridge is broken and smooth
muscle relaxation ensues. II: under hypoxic condition, soluble guanylyl cyclase pro-
duces inosine cyclic 30 ,5'-monophosphate (cIMP) instead of cGMP, which activates
Rho-associated protein kinase (ROCK) and inhibits MLCP, resulting in contraction. III:
protein S-nitrosylated by NO. IIIa: S-nitrosylation increases the activity of SERCAwhich
accelerates calcium depletion and induces relaxation. IIIb: G protein-coupled receptors
(GPCR) can be directly S-nitrosylated by NO which impedes the binding of ligands for
the receptor or G-protein coupling. IIIc: S-nitrosylation of G protein-coupled receptor
kinase 2 (GRK2) prevents the desensitization and internalization of b-adrenoceptors.
IIId: S-nitrosylation of b-arrestin 2 increases receptor internalization.every cysteine residue in a protein becomes S-nitrosylated (185). Of
particular importance for the tone of vascular smooth muscle, S-
nitrosylation regulates the expression and functions of G protein-
coupled receptors (GPCRs); this mechanism also plays a role in
the regulation of vascular tone (185,236). For instance, NO and S-
nitrosothiols modulate the activity of GPCR kinase 2 (GRK2) which
phosphorylates b-adrenoceptors and induce receptor desensitiza-
tion and internalization to curtail G-protein signaling. Thus, NO and
S-nitrosothiols prevent the loss of b-adrenergic signaling in vivo by
S-nitrosylating GRK2, attenuating GRK2-mediated phosphorylation
of b-adrenoceptors and decreasing receptor desensitization and
internalization (236,237). In the heart, activation of b1 and b2-
adrenoceptors increases heart rate and atrial cardiac muscle
contractility (238e241); by contrast, activation of these receptors in
blood vessels induces vasodilatation (242e244). Thus, increased
NO production with greater S-nitrosylation of GRK2 (preventing
the loss of b-adrenergic signaling) may increase cardiac output and
improve perfusion of target organs. GPCRs also can be S-nitro-
sylated directly by chemical NO-donors; such S-nitrosylation of
muscarinic (245) or bradykinin receptors (246) disrupts their
coupling to G proteins. Likewise, S-nitrosoglutathione inhibits a1-
adrenoceptor-mediated vasoconstriction and ligand binding (247).
In addition, S-nitrosylation of cysteine 289 of the AT1 receptor
decreases its binding afﬁnity for angiotensin II (248). Cytosolic b-
arrestin binding to ligand-activated and GRK-phosphorylated
GPCRs sterically impedes the interaction of G-proteins with acti-
vated GPCRs, resulting in GPCR signaling termination (249e251).
Also, b-arrestin 2, can be S-nitrosylated on cysteine 410 by
endogenous NO and S-nitrosogluthathione, which promotes
binding of b-arrestin 2 to clathrin heavy chain/b-adaptin, thereby
accelerating receptor internalization (252).
By contrast to its vasodilator effects, NO mediates hypoxic
augmentation of contractions in coronary arteries, which is
dependent on sGC but independent of cGMP (253,254): Indeed,
acute hypoxia induces a transient further increase in tension in
contracted coronary arterial rings, which can be abolished by L-
NAME [L-NG-Nitroarginine methyl ester, NO synthase (NOS) in-
hibitor] or ODQ (1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one, sGC
inhibitor) but is restored by the NO-donor DETA NONOate. How-
ever, the cGMP levels do not, but those of cyclic inosine mono-
phosphate (cIMP) increase under these conditions and inhibitors of
protein kinase G (the canonical target of cGMP) do not inhibit the
hypoxic augmentation, indicating a novel, cIMP-mediated signaling
mechanism for NO different from the classic NO-sGC-cGMP-
relaxation pathway (Fig. 6) (253e256).
5. NO deﬁciency
In patients with hypertension or prehypertension, and salt-
sensitive hypertensive Dahl rats, the NO-mediated relaxation in
response to acetylcholine is blunted (257e263). However, the
relaxation of vascular smoothmuscle to NO donors (such as sodium
nitroprusside) is not altered (260e262,264,265). Thus, the reduced
NO bioavailability can be attributed to a decreased NO production
and/or an increased NO degradation. This conclusion is based on
the evidence discussed in the following sections, taking mainly the
SHR as an example of endothelial dysfunction.
5.1. Decreased NO precursors
L-arginine, the precursor of NO, is an essential amino acid for
young mammals. In healthy human adults, L-arginine can be syn-
thesized from L-citrulline by endogenous (de novo) synthesis (266).
Therefore, decreased availability of L-arginine and L-citrulline can
contribute to NO deﬁciency (266e270). Even when the L-arginine
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maximal rate of the enzyme-mediated reaction] for NOS, reduced
NO generation can occur; this can be due to decreased competitive
displacement by the endogenous competitive inhibitor asymmet-
rical dimethyl arginine [ADMA (Fig. 4), which is a metabolic by-
product created during protein methylation in the cytoplasm of
all human cells (268,271e273)]. This is deﬁned as the arginine
paradox: the dependence of cellular NO production on the exoge-
nous L-arginine concentration despite the theoretical saturation of
NOS enzymes by intracellular L-arginine (268). The plasma level of
L-arginine is not signiﬁcantly different in SHR and WKY, but L-
arginine metabolism is impaired in the former under stress con-
ditions and by nicardipine (a dihydropyridine type calcium channel
blocker) (274,275). Long-term L-arginine supplementation im-
proves endothelial function of small coronary arteries and attenu-
ates cardiac hypertrophy in the SHR (276,277). L-citrulline, the
precursor of L-arginine, can dilate retinal arterioles through NO-
and prostaglandin-dependent pathways without signiﬁcantly
changing arterial blood pressure, heart rate and fundus blood ﬂow
(278). On the other hand, elevated levels of arginase, which cata-
lyzes the transformation of L-arginine to ornithine and urea,
compete with NOS for the available L-arginine thus reducing the
production of NO and increasing the release of O2$ (279,280).
Inhibition of arginase reduces blood pressure and improves
vascular function in the SHR (281,282).
5.2. Impairment of NO synthesis
A decreased NO production could be due to reduced eNOS
expression/presence in adult and old (around 36 and 72 weeks)
SHR (36,283). However, endothelial dysfunction is associated with
an increase rather than a decrease of eNOS expression (284e286).
The up-regulated expression of eNOS in situations of endothelial
dysfunction is likely to be the consequence of an elevated pro-
duction of hydrogen peroxide, which is a dismutation product of
O2$, and can increase the protein presence of eNOS by increasing
the production and extending the half-life of its mRNA (287).
Uncoupling of eNOS has been reported in essential hypertensive
patients with endothelial dysfunction (288), diabetes mellitus
(289), or hypercholesterolemia (290) as well as in nitroglycerin-
treated patients (291) and chronic smokers (292). In addition,
eNOS uncoupling also can be observed in isolated blood vessels
from animals with hypertension (99,100,293e295) or diabetes
(296), and after induction of nitroglycerin tolerance (297). Several
mechanisms contribute to the eNOS uncoupling causing endothe-
lial dysfunction. Thus, vascular nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH oxidase) plays a crucial role in eNOS
uncoupling, as it produces ROS, which leads to oxidation of the
critical co-factor BH4 (298,299). Particularly, the direct reaction
product of O2$ and NO$, ONOO, also oxidizes BH4 to the BH3$
radical (Fig. 4) (300,301). This reaction can be reversed by vitamin C
(302). Oxidative stress disrupts the balance between de novo syn-
thesis of BH4 and its oxidation/degradation, thus leading to exces-
sive depletion (303,304). For example, the BH4 level is reduced in
the plasma of SHR compared to WKY rats (305), in the aorta of
insulin-resistant rats (306), and in DOCA-salt-treated hypertensive
rats (298).
5.3. Increased NO degradation
NO can undergo a number of reactions under biological condi-
tions. It is spontaneously inactivated in the presence of oxygen or
O2$ (307,308). It also can be scavenged by oxyhemoglobin to yield
methemoglobin and inorganic nitrate (309). In addition, NO reacts
with thiol groups in proteins to yield S-nitrosothiols (235,310). Thepresence of O2$ causes rapid and nearly complete inactivation of
endothelium-derived NO (311e314). ROS produced by cyclo-
oxygenases also inactivate the NO produced by cytochrome P450
reductase in SHR arteries (90). The biological half-life of NO varies
in function of the oxygen tension and the O2$ concentration
(313,315e318). In the concentration range of 10e50 nM, NO has a
half-life of about three to ﬁve seconds; in concentrations in excess
of 300 nM, its half-life is longer than 30 s (308). Thus, the accel-
erated degradation of NO can worsen its deﬁcient production.
6. Conclusions
NO is a free radical which not only is present in the environment
but also can be produced in the body as a vital signaling molecule.
In the vasculature, NO stimulates sGC to produce cGMP, decreases
the intracellular concentration of calcium, causes relaxation of
vascular smooth muscle and thus is a potent vasodilator. Besides
activating sGC, NO reacts with cysteine thiols to form S-nitrosylated
proteins, which increase the activity of SERCA and reduce the
intracellular concentration of free calcium ions, also facilitating
relaxation. S-nitrosylation of GRK2 prevents b-adrenoceptor from
desensitization and internalization, enhancing the vasodilator
response to catecholamines. However, NO also mediates hypoxic
augmentation of contraction in coronary arteries, a response which
depends on sGC but is independent of cGMP production. NO can be
produced from L-arginine, S-nitrosothiols and nitrate/nitrite in the
vascular wall by different enzymes under different conditions.
Endothelial dysfunction does not simply result from a decreased
NO production by eNOS, but can also involve a complex combina-
tion of decreased availability of L-arginine, enzyme dysfunction and
increased degradation. Thus, when analyzing the role of NO in the
vascular wall, different signaling pathways and sources, and alter-
ations in bioavailability should be considered.
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